Regen BioPharma Raises $112,500 Note and Signs $10M Discounted Equity Line With Coventry
Summary
Regen BioPharma signed a $125,000 discounted convertible note (netting $112,500, most of it used to retire $71,557 of old convertible debt) and a $10 million, 36-month equity line priced at 80% of the lowest recent trading price.
Key Events · Financing and Capital Events · RGBP
-
Discounted Note and Equity Line Signed
On October 27, 2026 the company sold Coventry Enterprises a $125,000 10% unsecured note at a $12,500 original issue discount, netting $112,500, and signed a 36-month common stock purchase agreement for up to $10,000,000.
-
Most Note Proceeds Retire Old Debt
$71,557 of existing convertible indebtedness and accrued interest was satisfied from the note proceeds, leaving little new operating cash; the note repays in 8 monthly payments of $17,187.50 starting six months after funding.
-
Equity Line Priced at 20% Discount
Drawdowns are priced at 80% of the lowest trading price during the ten business days before the drawdown notice, capped at the lesser of $250,000 or 200% of average daily traded value per draw, and require an effective S-1 covering Coventry's resale.
-
Default Triggers Deeply Discounted Conversion
The note converts only after an Event of Default, at 90% of the lowest per-share trading price over the 20 trading days preceding conversion, with a 4.99% beneficial ownership blocker.
Analysis · RGBP · Life Sciences
Survival capital has arrived on punitive terms for Regen BioPharma, which reported only $239 of cash and a going-concern warning in its August 10-Q. The immediate cash is small: a $125,000 note that nets $112,500 after a $12,500 original issue discount, and $71,557 of it goes straight to retiring existing convertible debt rather than funding operations. The larger piece is a $10,000,000 equity line under which Coventry buys stock at 80% of the lowest trading price over the prior ten business days — a 20% discount to the market's weakest print — and the company can only draw once an S-1 registering Coventry's resale is effective. The note converts only after a default, at 90% of the lowest 20-day price, so a payment miss hands Coventry deeply discounted shares. With 2.03 billion shares already outstanding against 5.8 billion authorized, each draw and each default conversion adds supply into a stock trading at a fraction of a cent.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGBP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $194.6K. The 52-week trading range was $0.00 to $0.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.